Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as powerful tools for weight management, with clinical trials showing average weight loss of 10 to 22 percent of body weight over 68 weeks. However, not everyone is a candidate for these medications, and PlexusDx uses evidence-based criteria to identify who benefits most from GLP-1 therapy. Understanding your eligibility opens the door to personalized, medically supervised weight loss.

BMI Requirements and Weight Loss Candidacy

Body Mass Index (BMI) serves as the primary screening tool for GLP-1 eligibility. Adults with a BMI of 30 or higher qualify for GLP-1 therapy as a treatment for obesity. Those with a BMI between 27 and 29.9 may also qualify if they have weight-related health conditions such as type 2 diabetes, high blood pressure, or elevated cholesterol.

PlexusDx evaluates your complete health profile rather than relying on BMI alone. This personalized approach ensures that individuals whose weight significantly impacts their quality of life or disease risk receive appropriate treatment. Your healthcare provider at PlexusDx will review your medical history, current medications, and metabolic markers to determine if GLP-1 therapy aligns with your health goals.

Medical Conditions That Support GLP-1 Eligibility

Certain chronic conditions expand eligibility for GLP-1 receptor agonists beyond BMI thresholds. Type 2 diabetes, cardiovascular disease, metabolic syndrome, sleep apnea, and fatty liver disease all represent health reasons to consider GLP-1 treatment. These conditions often improve alongside weight loss, creating a dual benefit for patients managing multiple metabolic problems.

Individuals with a family history of heart disease, stroke, or early mortality may also qualify, as weight loss through GLP-1 therapy can reduce inherited cardiovascular risk. PlexusDx considers your complete clinical picture, including blood pressure, fasting glucose, and lipid profiles. This comprehensive screening ensures that treatment recommendations support your long-term health outcomes, not just the number on the scale.

Age, Pregnancy, and Medication Contraindications

GLP-1 medications are approved for adults 18 and older. Pregnant women and those planning pregnancy should not use these medications, as their safety during pregnancy has not been established. Nursing mothers are also advised to avoid GLP-1 therapy until they complete breastfeeding, as the drugs may pass into breast milk.

Certain medications and medical histories may contraindicate GLP-1 use. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) is an absolute contraindication. Additionally, individuals with severe kidney disease, active pancreatitis, or unstable cardiovascular conditions require careful evaluation. PlexusDx reviews all current medications to identify potential interactions and ensure GLP-1 therapy will not compromise your existing treatment plans.

How PlexusDx Assesses Your GLP-1 Eligibility

PlexusDx begins your eligibility assessment with a detailed questionnaire covering medical history, current symptoms, medications, and weight-loss attempts. This initial screening takes 10 to 15 minutes and can be completed online from any location in the United States. No insurance is required, and PlexusDx serves all 50 states with treatment plans starting at $149 per month for compounded semaglutide injection.

After your initial assessment, PlexusDx connects you with a licensed healthcare provider who reviews your information and determines candidacy. If you qualify, treatment begins immediately, and your dose is adjusted based on tolerance and results. For patients seeking deeper personalization, the Precision Peptide Genetic Test ($99 add-on after your first month) identifies how your genes influence peptide-pathway metabolism, helping optimize your specific GLP-1 compound choice and dosing strategy. Your dose may need to go up. Your price won't—PlexusDx keeps monthly costs flat across all commitment tiers.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I start GLP-1 therapy if my BMI is below 30?

Yes. You may qualify if your BMI is 27 to 29.9 and you have weight-related health conditions like type 2 diabetes, high blood pressure, or heart disease. PlexusDx evaluates your complete medical history to determine eligibility, not BMI alone.

What clinical evidence supports GLP-1 for weight loss?

Multiple randomized controlled trials show GLP-1 receptor agonists produce 10 to 22 percent weight loss over 68 weeks, with additional improvements in blood sugar control, blood pressure, and cardiovascular outcomes. These medications work by slowing gastric emptying and reducing hunger signals in the brain.

How much does semaglutide cost at PlexusDx, and do I need insurance?

Compounded semaglutide injection starts at $149 per month with no insurance required. PlexusDx serves all 50 states and accepts HSA and FSA payments. Your dose may increase over time, but your monthly price remains flat across all commitment tiers.

Are there serious side effects I should know about before starting?

Common side effects include nausea, vomiting, and constipation, which often improve within weeks. Serious but rare risks include pancreatitis and thyroid concerns. PlexusDx screens for contraindications and monitors you throughout treatment to ensure safety and tolerability.

How does the Precision Peptide Genetic Test help determine my best GLP-1 option?

The Precision Peptide Genetic Test analyzes variants in genes like GLP1R, GIPR, FTO, and MC4R that influence how your body responds to GLP-1 compounds. PlexusDx maps 14 pathways and 150+ genetic insights to recommend whether semaglutide, tirzepatide, or a dual compound best matches your metabolic profile.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves